Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Ist Teil von
The New England journal of medicine, 2009-04, Vol.360 (14), p.1395-1407
Ort / Verlag
Waltham, MA: Massachusetts Medical Society
Erscheinungsjahr
2009
Quelle
MEDLINE
Beschreibungen/Notizen
In a multicenter, randomized trial, 2776 patients undergoing maintenance hemodialysis who were not currently taking a statin were randomly assigned to rosuvastatin or placebo. At a median of 3.8 years of follow-up, rates of the composite primary end point of death from cardiovascular causes, myocardial infarction, or stroke did not differ significantly between the two study groups.
Patients undergoing maintenance hemodialysis were randomly assigned to rosuvastatin or placebo. At a median of 3.8 years of follow-up, rates of the composite primary end point of death from cardiovascular causes, myocardial infarction, or stroke did not differ significantly between the two study groups.
Patients undergoing maintenance hemodialysis have a greatly increased risk of premature cardiovascular disease.
1
,
2
However, the pattern of cardiovascular disease in such patients differs from that in the general population, and although the risk of myocardial infarction is increased, other cardiovascular events, such as sudden cardiac death and heart failure, predominate.
1
–
3
Moreover, the relationship between cardiovascular disease and conventional risk factors is inconsistent, inverse, or U-shaped.
1
,
2
,
4
Since low-density lipoprotein (LDL) cholesterol levels may be low or normal in patients with advanced renal disease, there is particular uncertainty regarding the use of lipid-lowering therapy.
1
,
2
,
4
,
5
Statin . . .